Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection.

Hagani AB, Rivière I, Tan C, Krause A, Sadelain M.

J Gene Med. 1999 Sep-Oct;1(5):341-51.

PMID:
10738551
2.

Generation of high-titer pseudotyped retroviral vectors with very broad host range.

Yee JK, Friedmann T, Burns JC.

Methods Cell Biol. 1994;43 Pt A:99-112. Review.

PMID:
7823872
3.

Development of HIV vectors for anti-HIV gene therapy.

Poeschla E, Corbeau P, Wong-Staal F.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11395-9. Review.

4.

T lymphocytes as targets of gene transfer with Moloney-type retroviral vectors.

Ayuk FA, Zander AR, Fehse B.

Curr Gene Ther. 2001 Nov;1(4):325-37. Review.

PMID:
12109060
5.

[Deep lung--cellular reaction to HIV].

Tavares Marques MA, Alves V, Duque V, Botelho MF.

Rev Port Pneumol. 2007 Mar-Apr;13(2):175-212. Review. Portuguese.

PMID:
17492233
6.

Retroviral vector targeting for gene therapy.

Günzburg WH, Fleuchaus A, Saller R, Salmons B.

Cytokines Mol Ther. 1996 Sep;2(3):177-84. Review.

PMID:
9384702
7.

Cell targeting by murine retroviral vectors.

Karavanas G, Marin M, Salmons B, Günzburg WH, Piechaczyk M.

Crit Rev Oncol Hematol. 1998 Jun;28(1):7-30. Review.

PMID:
9715768
8.

Retrovirus vector-mediated gene transfer into hepatocytes.

Friedmann T, Xu L, Wolff J, Yee JK, Miyanohara A.

Mol Biol Med. 1989 Apr;6(2):117-25. Review.

PMID:
2693887
9.

Progress towards gene therapy for HIV infection.

Yu M, Poeschla E, Wong-Staal F.

Gene Ther. 1994 Jan;1(1):13-26. Review.

PMID:
7584055
10.

Gene transfer into haemopoietic cells.

Stocking C, Baum C.

Baillieres Clin Haematol. 1997 Sep;10(3):445-65. Review.

PMID:
9421610
11.

Retroviral stem cell gene therapy.

Havenga M, Hoogerbrugge P, Valerio D, van Es HH.

Stem Cells. 1997;15(3):162-79. Review.

12.

Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Hurez V, Hautton RD, Oliver J, Matthews RJ, Weaver CK.

Immunol Res. 2002;26(1-3):131-41. Review.

PMID:
12403352
13.

Primary T lymphocytes as targets for gene therapy.

Hanazono Y, Brown KE, Dunbar CE.

J Hematother Stem Cell Res. 2000 Oct;9(5):611-20. Review.

PMID:
11091484
14.

Development of a flexible and specific gene delivery system for production of murine tumor models.

Fisher GH, Orsulic S, Holland E, Hively WP, Li Y, Lewis BC, Williams BO, Varmus HE.

Oncogene. 1999 Sep 20;18(38):5253-60. Review.

15.

Establishment of a therapeutic model for retroviral infection using the genetic resistance mechanism of the host.

Kitagawa M, Aizawa S, Ikeda H, Hirokawa K.

Pathol Int. 1996 Oct;46(10):719-25. Review.

PMID:
8916140
16.

[T-lymphocytes disorders in pulmonary sarcoidosis].

Gormand F, Ecochard D, Aloui R, Perrin-Fayolle M, Pacheco Y.

Rev Mal Respir. 1990;7(3):187-94. Review. French.

PMID:
1694590
17.

Gene therapy for autoimmune disease.

Fathman CG, Costa GL, Seroogy CM.

Clin Immunol. 2000 Apr;95(1 Pt 2):S39-43. Review.

PMID:
10729236
18.

Mechanisms of cell killing/cytopathic effects by nonhuman retroviruses.

Temin HM.

Rev Infect Dis. 1988 Mar-Apr;10(2):399-405. Review.

PMID:
2836939
19.

New approaches towards ex vivo and in vivo gene therapy.

Hauser H, Spitzer D, Verhoeyen E, Unsinger J, Wirth D.

Cells Tissues Organs. 2000;167(2-3):75-80. Review.

PMID:
10971031
20.

Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis.

Czaja AJ.

Curr Pharm Des. 2011;17(29):3120-40. Review.

PMID:
21902661

Supplemental Content

Support Center